Drug intelligence / Profile preview

JBPOS0607

Development stage: Preclinical
Lead developer: Bio-Pharm Solutions
Modality: Small Molecules

Overview

JBPOS0607 is a preclinical-stage small molecule developed by Bio-Pharm Solutions for the treatment of Parkinson's disease, Alzheimer's disease, and epilepsy. The compound is part of the company's neurotherapeutics pipeline, which focuses on the modulation of glutamate receptors and ion channels to address central nervous system disorders. As of 2024, JBPOS0607 is undergoing preclinical studies to evaluate its potential as a neuroprotective and anti-seizure agent. The drug aims to provide therapeutic benefits by addressing neurodegeneration and hyperexcitability associated with these chronic neurological conditions.

Targets

GluR (Glutamate receptors)

Beyond the preview

Go deeper on JBPOS0607.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JBPOS0607.

Explore the full profile